Status: Recruiting
Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation
This study investigates the safety and tolerability of Nintedanib in patients with bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic cell transplantation. All study patients with BOS will be treated with the study drug Nintedanib (300 mg/day) as an add-on therapy to their basic immunosuppressive treatment over a 12-months treatment period.
Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University Hospital, Basel, SwitzerlandUpdated: Dec 15, 2025Locations: 3
Eligibility criteria
Time interval from transplant </= 5 years at the time of inclusion [+5]
Known intolerance to Nintedanib or any of its component [+10]